Eupraxia Pharmaceuticals Inc. (EPRX)
Eupraxia Pharmaceuticals Inc. (EPRX) is a Healthcare stock tracked by StreetAlpha. It last closed at $5.80 on Nov 20, down 5.23% on the day.
Key Stats
Fiscal 2025Not reported for this period.
From EPRX's SEC filings, latest 40-F for the period ending Dec 31, 2025 (filed Mar 13). Per share figures are left out because the US listing can represent a different number of shares.
Earnings
Full earnings history →Analyst Ratings & Price Targets
Analyst Ratings →- Every upgrade, downgrade and initiation as it happens
- Every price target change, raised or cut
- Consensus rating with the average, high and low targets
- Each firm's full rating history on EPRX
Technical AnalysisPrices may be delayed
The stock is 21% below its 20 day and 29% below its 50 day average. It is 24% below its 200 day average, so the longer trend is down. Momentum is weak (RSI 35), near oversold. The nearest support is the swing low (Jul 24) at $5.72, and the nearest resistance the Pivot at $5.97.
| RSI (14) | 35.30 | Weak, oversold below 30 | Neutral |
| MACD | -0.24 | Below its signal line | Bearish |
| Stochastic | 3.1 | Near the bottom of its range | Oversold |
| ADX (14) | 15.8 | No clear trend | |
| Williams %R | -96.1 | Oversold below −80, overbought above −20 | Oversold |
| CCI (20) | -153.1 | Oversold below −100, overbought above 100 | Oversold |
| Rate of change | −15.8% | Change over 10 sessions | Bearish |
| ATR (14) | $0.59 | Typical daily range, 10.1% of price |
| RSI (14) | 41.20 | Middle of its range | Neutral |
| MACD | -0.01 | Below its signal line | Bearish |
| Stochastic | 29.0 | Middle of its range | Neutral |
| ADX (14) | 16.1 | No clear trend | |
| Williams %R | -96.9 | Oversold below −80, overbought above −20 | Oversold |
| CCI (20) | -64.1 | Oversold below −100, overbought above 100 | Neutral |
| Rate of change | −31.1% | Change over 10 sessions | Bearish |
| ATR (14) | $1.16 | Typical daily range, 19.9% of price |
What happened before
See how EPRX did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record. Free with an account.
Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.
Whale Options FlowPrices may be delayed
90DNo whale options trades in EPRX in the last 90 days.
Dark PoolPrices may be delayed
30DEPRX Institutional Ownership
Full report →- ●33 buying vs 29 selling
- ▲Shares held by funds +22.9%
- ▲Funds holding +2
- ▼Superinvestors: 1 added, 2 cut
- ●Put/call not meaningful
| Q3 2026 | This quarter | Last quarter | Change |
|---|---|---|---|
| Funds holding | 70 | 68 | +2.9% |
| In funds' top 10 | 2 | 0 | – |
| Held by funds | – | – | – |
| New / increased | 11 / 22 | 16 / 21 | −10.8% |
| Reduced / sold out | 20 / 9 | 18 / 6 | +20.8% |
| Put/call ratio | – | – | – |
From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.
AI Auto Pilots
Paper tradingStreetAlpha runs autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether EPRX is in one of them and how their past EPRX trades turned out.
EPRX News Tone and PricePrices may be delayed
Macro & Market News
All StreetAlpha news →StreetAlpha hasn't covered EPRX in an article yet. Here's the latest on the wider market.
- Open Market Sale Agreement Sm
- Eupraxia Pharmaceuticals Establishes At-The-Market Offering Program
- Condensed Consolidated Interim Financial Statements
- Eupraxia Pharmaceuticals Reports Third Quarter 2026 Financial Results
- Eupraxia Pharmaceuticals to Participate at Upcoming Conferences and Host a Virtual Analyst Day


